SAN CARLOS, Calif., Sept. 19 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present at the 2007 UBS Global Life Sciences Conference on Tuesday, September 25, 2007. Anthony DiTonno, President and Chief Executive Officer, and Jeffery Tobias, Chief Medical Officer, will be presenting.
Date: Tuesday, September 25, 2007
Time: 9:00 a.m. EDT
Place: Grand Hyatt Hotel, New York, NY
An audio Web cast of the Company's presentation will be available by going to the investor relations section of NeurogesX's Web site at http://www.neurogesx.com. A replay of the presentation will be available for 30 days.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on
developing novel pain management therapies. Its initial focus is on chronic
peripheral neuropathic pain, including postherpetic neuralgia (PHN),
painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic
neuropathy. NeurogesX' late stage product portfolio is led by its product
candidate NGX-4010, a topical patch designed to manage pain associated with
peripheral neuropathic pain conditions, that the company believes offers
significant advantages over other pain therapies. Three Phase 3 clinical
trials with NGX-4010 have been completed and have met their primary
Copyright©2007 PR Newswire.
All rights reserved